FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity
DAIC
MARCH 8, 2024
mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established CVD and without diabetes. 1 The most common adverse event leading to discontinuation was gastrointestinal disorders, occurring in 10% of patients in the Wegovy group and 2% in the placebo group. 2 Wegovy 2.4 with placebo.
111 
Let's personalize your content